On the therapeutic potential of MAPK4 in triple-negative breast cancer
F. Boudghene-Stambouli, M. Soulez, N. Ronkina, A. Doerrie, A. Kotlyarov, O.-M. Seternes, M. Gaestel, S. Meloche
The paper critiques Wang et al.'s study on ERK4's role in TNBC, arguing that methodological flaws undermine their conclusion that ERK4 is a therapeutic target.
bioRxiv · Aug 24, 2022 · PreprintCancer Biology